Favipiravir in patients infected with COVID-19

Phase 2

• Conditions: patients infected with COVID-19; Coronavirus

• Registration Number: JPRN-jRCTs031190226
• Lead Sponsor: Tokue Yutaka

Brief Summary

There was no difference in adjusted mean change in CRP between cohorts 1 and 2: -1.57 (95% CI -3.02 to -0.12) mg/dL and -2.29 (95% CI -3.77 to -0.81) mg/dL, respectively (p=0.500). The negative conversion rate of SARS-CoV-2 was higher in cohort 2 than in cohort 1 (odds ratio 2.67 (95% CI, 1.09 to 6.52), p=0.032), and a trend of greater efficacy was seen in patients with older age, lower BMI, lower baseline CRP, and without steroid use.

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2020-02-27
• Study Completion: 2021-05-31
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

positive result for COVID-19 detection test
fever above 37.5 degree Celsius, or pneumonia shadow on chest X-ray or CT-scan
hospital admission

Exclusion Criteria

pregnancy
lactation

Study & Design

• Study Type: Interventional
• Study Design: Not specified